Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

This nonrandomized controlled trial including 223 patients with advanced solid tumors found that avelumab plus talazoparib was safe and well tolerated. Objective responses were mostly observed in patients with BRCA-altered tumors, with limited activity seen in patients with non–BRCA-altered DNA damage response (DDR)–positive tumors; however, prolonged duration of response was observed in patients with triple-negative breast cancer; hormone receptor–positive, human epidermal growth factor receptor 2–negative, DDR-positive breast cancer; and BRCA-altered ovarian cancer.